摘要
目的探讨临床奥拉西坦注射液在高血压脑梗死患者神经系统中的治疗效果。方法选取贵阳医学院第二附属医院2012年1月~2013年12月间80例高血压脑梗死患者为临床研究对象,将其按照随机数字表法分为对照组和研究组(n=40)。对照组给予基础治疗,研究组在基础治疗上应用奥拉西坦注射液治疗,观察2组临床疗效和神经功能缺损状况以及不良反应。结果研究组总有效率92.5%,对照组总有效率70.0%,研究组总有效率明显的高于对照组,有统计学意义(P<0.05)。治疗前研究组和对照组的NIHSS评分比较无明显的差异,无统计学差异。治疗后研究组和对照组的NIHSS评分较治疗前有明显的改善,且组间的数据比较差异有统计学意义(P<0.05)。研究组不良反应发生率为2.5%;对照组不良反应发生率为5.0%。研究组与对照组患者的不良反应发生率比较无明显的差异,无统计学差异。结论临床中高血压脑梗死患者在常规治疗上应用奥拉西坦注射液治疗能够改善神经系统损害,并且提高临床疗效,且出现的不良反应少。
Objective To investigate the clinical effects of oxiracetam injection in treatment of cerebral infarction in hypertensive patients with neurological damage. Methods From January 2012 to December 2013,80 cases of cerebral infarction patients with hypertension were selected which were randomly divided into a control group and study group,each had 40 cases. The control group received basic treatment,the study group applied oxiracetam injection treatment on the basis of treatment,clinical efficacy and neurological deficit situation and adverse reactions were observed. Results The total effective rate was 92. 5% in the control group,the total efficiency of 70. 0% in control group,and the total efficiency of the study group was significantly higher than control group( P < 0. 05). There was no significant difference between the treatment and control group prior to the study of NIHSS scores. After treatment,NIHSS score of the study group and the control group were significantly lower than before treatment and the difference between two groups were statistically significant( P < 0. 05). Adverse reactions in study group was 2. 5%; adverse reactions occurred in the control group was5. 0%. There was no significant difference. Conclusion The clinical application of oxiracetam injection in treatment of patients with cerebral infarction and hypertension can improve nervous system damage,and improve the clinical efficacy and has fewer adverse reactions.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第6期150-152,157,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
2008年江苏省卫生厅项目(H200828)
关键词
高血压脑梗死
奥拉西坦
神经系统损害
临床疗效
hypertensive cerebral infarction
oxiracetam
nervous system damage
clinical efficacy
